Anti-CD37 Antibody Pipeline Insight, 2018 Report - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 31, 2018--The “Anti-CD37 Antibody - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Anti-CD37 Antibody - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD37 Antibody development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Descriptive coverage of pipeline development activities for Anti-CD37 Antibody - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Anti-CD37 Antibody - Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Anti-CD37 Antibody
4. Comparative Analysis
5. Anti-CD37 Antibody Pipeline Products in Clinical StagesProduct Description Research and Development Product Development Activities
Other product profiles in the detailed report..
6. Anti-CD37 Antibody Pipeline Products in Non-clinical StagesProduct Description Research and Development Product Development Activities
7. Therapeutic Assessment: Active ProductsPipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline ProductsProduct Description Research and Development Product Development Activities Reason for dormancy/discontinuation
Companies MentionedNordic Nanovector ImmunoGen Boehringer Ingelheim
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9c5w6m/anticd37?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180831005454/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/31/2018 03:19 PM/DISC: 08/31/2018 03:19 PM